Phase 1 Hemophilia Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hemophilia A
Hoffmann-La Roche5 enrolled2 locationsNCT07226206
Recruiting
Phase 1
Lentiviral FVIII Gene Therapy
Hemophilia A
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03217032
Recruiting
Phase 1
Lentiviral FIX Gene Therapy
Hemophilia B
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03961243
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Hemophilia B
Regeneron Pharmaceuticals130 enrolled41 locationsNCT06379789
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hemophilia A
Hoffmann-La Roche60 enrolled14 locationsNCT05987449
Recruiting
Phase 1
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia
Bleeding and Clotting Disorders Institute Peoria, Illinois40 enrolled12 locationsNCT05500807
Recruiting
Phase 1
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Severe Hemophilia A
Pfizer15 enrolled4 locationsNCT06703606
Recruiting
Phase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Healthy ParticipantsHemophilia AHemophilia B+1 more
Equilibra Bioscience LLC31 enrolled10 locationsNCT06349473
Recruiting
Phase 1
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
Hemophilia A
Swedish Orphan Biovitrum24 enrolled8 locationsNCT06579144
Recruiting
Phase 1Phase 2
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Hemophilia BHemophilia B, Moderately Severe or Severe
Be Biopharma24 enrolled4 locationsNCT06611436
Recruiting
Phase 1Phase 2
Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)
Hemophilia B
Biocad28 enrolled17 locationsNCT06120582
Recruiting
Phase 1
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China9 enrolled1 locationNCT05709288
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT05641610
Recruiting
Phase 1Phase 2
ASC618 Gene Therapy in Hemophilia A Patients
Hemophilia A
ASC Therapeutics12 enrolled1 locationNCT04676048
Completed
Phase 1
Understanding the blood level of a new coagulant factor VIIa in participants with congenital Haemophilia A
Congenital Hemophilia A in subjects with or without Inhibitors to Factor VIII
LFB USA, Inc.28 enrolled3 locationsACTRN12620001152910